NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT03295565 2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3 Completed
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT02215096 2020-10-22
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Completed
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT01663415 2012-09-17
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 2 Withdrawn